Advancing Bioanalytical Best Practices: Key Insights from the GCC
The bioanalytical landscape is evolving faster than ever, driven by complex molecular therapeutics, innovative assay platforms, and a growing need for regulatory harmonization. In response, the Global CRO Consortium (GCC) has published a comprehensive white paper highlighting critical discussions, industry trends, and best practices across pharmacokinetics (PK), immunogenicity, biomarker analysis, and emerging regulatory oversight.
This summary captures the key insights, while the full white paper provides detailed guidance, case studies, and actionable recommendations.
Cross-Validation and Multi-Laboratory Studies
Cross-validation is a cornerstone of reliable bioanalysis, particularly when data from multiple laboratories or assays support the same submission, such as bioavailability (BA) or bioequivalence (BE) studies.
• Best Practices: Include both quality controls (QCs) and study samples when feasible to strengthen comparability.
• Regulatory Guidance: ICH M10 provides high-level recommendations, but ambiguity remains in terminology (e.g., “triplicate” can mean different things depending on the lab).
• Key Considerations: Handling unavailable incurred samples, pooled versus selectivity samples, and clear protocol ownership are critical for robust cross-validation planning.
Anti-Drug and Neutralizing Antibody Assays
Unlike PK assays, ADA and NAb assays lack formal cross-validation requirements, necessitating an upfront plan tailored to study objectives.
• ADA Assays: Consider whether categorical (positive/negative) or quantitative data (e.g., minimum significant ratio) are needed. Method comparability should cover both screening and confirmatory formats. A suggested approach: evaluate ≥60 samples across reference and comparator labs, with a mix of negative, low-positive, and high-positive samples.
• Neutralizing Antibodies (NAb): Cell-based assays add complexity due to poor portability and variable sensitivities. GCC recommends dedicated discussions and surveys to gather cross-industry experience.
Cross-Platform Comparability
New analytical technologies—LC-MS/MS, LBA, ELISA, and ultrasensitive platforms like Simoa™ require careful consideration when comparing results across instruments or methods.
• LC-MS/MS Recommendations: Use serial dilutions, triplicate evaluations, and back-calculated mean concentrations to assess inter-lab differences. Target %Difference ≤10%.
• Ultrasensitive Immunoassays: Prioritize drug tolerance over maximal sensitivity, using stoichiometric shifts, pre-treatment strategies, or bead-based capture to detect low-level antibodies.
Statistical Approaches
Robust statistical evaluation underpins cross-validation and method comparability:
• Regression and concordance analysis
• Modified Bland–Altman plots
• Mean bias and 95% limits of agreement
• Pre-defined a priori acceptance criteria
Sponsors remain responsible for the final comparative analysis, ensuring transparency and scientific rationale guide decisions.
Remote Regulatory Assessments (RRA)
Remote regulatory assessments are increasingly common, accelerated by COVID-19 adaptations. Key insights for CROs include:
• Preparation: Early scope clarification, centralized data uploads, and defined staff responsibilities
• Execution: Daily PowerPoint summaries, dedicated note-takers, and virtual tours to support effective inspection
• Outcome: Careful planning and communication significantly improve inspection success, as demonstrated by recent RRA case studies involving multiple studies and validations
Shedding and Biomarker Assays
Emerging modalities like viral vector shedding assays and tissue biomarker assays present unique challenges:
• Shedding Assays: Standardization of reporting units, reflex testing of high-risk samples, and fit-for-purpose sensitivity are key. Blood is generally used only when supported by PK or persistence considerations.
• Tissue Biomarker Assays: The GCC white paper focuses on molecular biomarkers in epithelial, muscular, nervous, skeletal, and connective tissue matrices. Rapid technological advances have outpaced regulatory guidance, highlighting the need for harmonized approaches.
Future Directions
The GCC continues to provide guidance on bioanalytical hot topics, encouraging harmonization of best practices, regulatory preparedness, and adoption of innovative assay technologies. The full white paper is a critical resource for CROs, sponsors, and laboratories aiming to align with current industry expectations and advance their bioanalytical strategies.
Download the full GCC White Paper to explore detailed recommendations, case studies, and actionable strategies for cross-validation, immunogenicity, and biomarker analysis.